DalCor is a clinical-stage biopharmaceutical company based in Montreal, Canada. The company is developing the first pharmacogenomic precision medicine, dalcetrapib, for the treatment of acute coronary syndrome in patients with the ADCY9 AA genotype. The company is conducting a confirmatory Phase 3 trial.
Acute coronary syndrome
CTI LSF II
Syndicate
Director
April 29, 2016
n/a
Series B
DalCor was created based on a Phase 3-ready precision cardiology asset from the Montreal Heart Institute, a leader in cardiology research
